Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis

Cardiovascular disease (CVD) is one of the most common comorbidities in breast cancer survivors. Recently, the target population and treatment period for aromatase inhibitor (AI) treatment in breast cancer patients has been expanding. However, information on adverse CVD events from the long-term use...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Jeong-Ju, Jung, Eun-Ae, Kim, Zisun, Kim, Bo-Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955032/
https://www.ncbi.nlm.nih.gov/pubmed/36826103
http://dx.doi.org/10.3390/curroncol30020142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955032/
https://www.ncbi.nlm.nih.gov/pubmed/36826103
http://dx.doi.org/10.3390/curroncol30020142

Ejemplares similares